Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 8/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268702 | 0.90 | CYP1A2 (0.63) | CYP1A2MAPTCYP2C19KMT2APGR | |
| Trifluoroacetic Acid SCHEMBL31693875 | 0.89 | CYP1A2 (0.44) | CYP1A2MAPTCYP2C19KMT2ABACE1 | |
| SCHEMBL20955239 | 0.87 | NR3C2 (0.52) | CYP1A2MAPTCYP2C19KMT2ABACE1 | |
| SCHEMBL29609794 | 0.87 | PGR (0.58) | CYP1A2MAPTCYP2C19KMT2APGR | |
| SCHEMBL25399999 | 0.87 | PGR (0.58) | CYP1A2MAPTCYP2C19KMT2APGR | |
| SCHEMBL4715658 | 0.85 | PGR (0.59) | CYP1A2MAPTCYP2C19KMT2APGR | |
| SCHEMBL23778368 | 0.84 | CYP1A2 (0.53) | CYP1A2MAPTCYP2C19KMT2APGR | |
| SCHEMBL15649741 | 0.83 | EPHX2 (0.59) | CYP1A2MAPTCYP2C19KMT2APGR | |
| SCHEMBL6637532 | 0.82 | BACE1 (0.52) | CYP1A2MAPTCYP2C19KMT2ABACE1 | |
| Hydrochloric Acid SCHEMBL6639312 | 0.81 | BACE1 (0.51) | CYP1A2MAPTCYP2C19KMT2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-2265588-B1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | VITAE PHARMACEUTICALS INC. | 2011-06-09 | — | — | US | disclosed |
| EP-2265588-A1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009108332-A1 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | CYP1A2 80/4885MAPT 2801/4885CYP2C19 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.